Results 131 to 140 of about 80,433 (248)

Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options. [PDF]

Hematol Transfus Cell Ther
Roshandel E, Lasemi MV, Mehravar M, Salimi M, Majidi M, Mohammadali F, Seraji HR, Hajifathali A.   +7 more
europepmc   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies. [PDF]

J Immunother Cancer
Li W, Yang J, Kong Q, Chen Z.
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. [PDF]

J Clin Oncol
Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L.   +23 more
europepmc   +1 more source

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

Chemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui, Tianlu Wang, Yaoyu Han, Yun Huang, Tien‐Hung Lan, Yunbin Zhou   +5 more
wiley   +1 more source

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors. [PDF]

J Immunother Cancer
Nardo G, Putti F, Indini A, Del Vecchio M, De Braud F, Di Nicola M, De Santis F.   +6 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting. [PDF]

Exp Hematol Oncol
Luo H, Ding Y, Zhao X.
europepmc   +1 more source

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source